Insider Selling: Crispr Therapeutics AG (CRSP) Insider Sells $704,320.00 in Stock

Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 31,000 shares of the company’s stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $22.72, for a total value of $704,320.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tyler Dylan-Hyde also recently made the following trade(s):

  • On Tuesday, January 2nd, Tyler Dylan-Hyde sold 38,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.64, for a total value of $822,320.00.
  • On Friday, December 28th, Tyler Dylan-Hyde sold 700 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.75, for a total value of $15,225.00.
  • On Friday, December 22nd, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.55, for a total value of $308,250.00.
  • On Friday, December 15th, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.90, for a total value of $283,500.00.

Crispr Therapeutics AG (NASDAQ:CRSP) opened at $23.91 on Friday. Crispr Therapeutics AG has a fifty-two week low of $11.63 and a fifty-two week high of $27.39. The company has a market capitalization of $964.78, a P/E ratio of -18.11 and a beta of 4.64.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). The company had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. Crispr Therapeutics’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter last year, the company earned ($2.77) earnings per share. research analysts anticipate that Crispr Therapeutics AG will post -2.46 earnings per share for the current fiscal year.

CRSP has been the subject of a number of research analyst reports. Barclays reissued a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a report on Friday, September 8th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. SunTrust Banks reissued a “hold” rating and set a $16.00 target price on shares of Crispr Therapeutics in a report on Friday, November 10th. BidaskClub cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Finally, Oppenheimer initiated coverage on Crispr Therapeutics in a report on Thursday, December 7th. They set a “hold” rating for the company. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $22.38.

Several hedge funds have recently bought and sold shares of CRSP. Allianz Asset Management GmbH purchased a new stake in shares of Crispr Therapeutics in the third quarter valued at approximately $2,384,000. Granahan Investment Management Inc. MA grew its position in shares of Crispr Therapeutics by 51.7% in the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after purchasing an additional 89,839 shares in the last quarter. Adams Street Partners LLC purchased a new stake in shares of Crispr Therapeutics in the third quarter valued at approximately $1,019,000. Hershey Trust Co. purchased a new stake in shares of Crispr Therapeutics in the third quarter valued at approximately $768,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Crispr Therapeutics in the third quarter valued at approximately $536,000. Institutional investors and hedge funds own 24.52% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/01/05/insider-selling-crispr-therapeutics-ag-crsp-insider-sells-704320-00-in-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply